Rozanolixizumab

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases[1].

Product Specifications

CAS Number

[1584645-37-3]

Product Name Alternative

UCB7665

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rozanolixizumab.html

Purity

99.40

Solubility

H2O

Smiles

[Rozanolixizumab]

Molecular Weight

(145.242 kDa)

References & Citations

[1]Smith B, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018;10 (7) :1111-1130.